| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-12 | Cempra (USA - NC) | $93.7 million | private placement | Infectious diseases | Private placement | |
| 2016-01-12 | Epizyme (USA - MA) | $ 130.1 million | private placement | Cancer - Oncology | Private placement | |
| 2016-01-12 | Valera, a Moderna Therapeutics' venture (USA - MA) | up to $20 million | grant | Bill & Melinda Gates Foundation | Infectious diseases | Grant |
| 2016-01-12 | Tmunity (USA - PA) | $10 million | financing round | Penn Medicine (USA - PA) Lilly Asia Ventures (China) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Financing round |
| 2016-01-11 | AB2 Bio (Switzerland) | CHF 21 million ($ 21 million - € 19.3 million) | series B financing round | undisclosed new and existing investors | Inflammatory diseases | Series B financing round |
| 2016-01-11 | Reneuron (UK) | £2.1 million | grant | Innovate UK (UK) | Regenerative Medicine | Grant |
| 2016-01-11 | Novimmune (Switzerland) | CHF 30 million ($29.8 million - €27.6 million) | financing round | Cancer - Oncology - Rare diseases - Immunological diseases | Financing round | |
| 2016-01-08 | Zymeworks (Canada) | $61.5 Million | series A financing round | BDC Capital (Canada) Celgene (USA - NJ) CTI Life Sciences Fund (Canada) Eli Lilly (USA - IN) Fonds de solidarité FTQ (Canada) Lumira Capital (Canada) Perceptive Advisors (USA - NY) Teralys Capital (Canada) Northleaf Venture Catalyst Fund (Canada) Brace Pharma Capital (USA - MD) Merlin Nexus (USA - NY) | Cancer - Oncology | Series A financing round |
| 2016-01-07 | C4 Therapeutics (USA - MA) | $73 million | series A financing round | Cobro Ventures (USA) Cormorant Asset Management (USA - MA) The Kraft Group (USA - MA) EG Capital Group (USA - NY) Roche (Switzerland) Novartis (Switzerland) angel investors | Series A financing round | |
| 2016-01-07 | Galena Biopharma (USA - OR) | $21.75 million | private placement | Cancer - Oncology | Private placement | |
| 2016-01-06 | Neovacs (France) | € 5 million | grant | Bpifrance (France) | Autoimmune diseases - Dermatological diseases | Grant |
| 2015-12-29 | Oryzon Genomics (Spain) | $ 1.3 million (€ 1.18 million) | loan | Ministry of Economy and Competitiveness of the Spanish Government (Spain) | Cancer - Oncology - Neurodegenerative diseases | Loan |
| 2015-12-22 | Merrimack Pharmaceuticals (USA - MA) | $175 million | private placement | Private placement | ||
| 2015-12-17 | Poietis (France) | €2.5 million | series A financing round, grant, loan | WiSEED (France) business angels BPIfrance (France) Conseil Régional d’Aquitaine (France) Banque Populaire Aquitaine Centre Atlantique (France) EADS Développement (France) Michelin Développement (France) | Technology - Services | Series A financing round |
| 2015-12-15 | GamaMabs Pharma (France) | €15 million | series B financing round | Edmond de Rothschild Investment Partners (EdRIP) (France) InnoBio (France) Irdinov (France) Alto Invest (France) iXO Private Equity) (France) | Cancer - Oncology | Series B financing round |
| 2015-12-15 | Oryzon Genomics (Spain) | IPO | Cancer - Oncology - Neurodegenerative diseases | IPO | ||
| 2015-12-14 | Seventure Partners (France) | € 160 million | fundraising | Danone (France) MultiCap Croissance (France) Natixis (France) Novartis (Switzerland) Tereos (France) Tournier (France) Unigrains (France) Bel (France) Lesaffre (France) | Fundraising | |
| 2015-12-11 | Kite Pharma (USA - CA) | $287.6 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2015-12-10 | Freeline Therapeutics (UK) | £25 million | series A financing round | Syncona (UK) | Hematologic diseases - Genetic diseases - Rare diseases | Series A financing round |
| 2015-12-10 | TETRA consortium lead by Videregen (UK) | € 6.8 million | grant | European Commission’s Horizon 2020 programme | Grant |
